메뉴 건너뛰기




Volumn 26, Issue 8, 2015, Pages 1667-1677

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

Author keywords

Diffuse large B cell lymphoma; Follicular lymphoma; Lenalidomide; Mantle cell lymphoma; Non Hodgkin lymphoma; Rituximab

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL; THALIDOMIDE;

EID: 84937708862     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv102     Document Type: Review
Times cited : (82)

References (68)
  • 5
    • 84875840492 scopus 로고    scopus 로고
    • Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 noninferiority trial
    • Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 noninferiority trial. Lancet 2013; 381: 1203-1210.
    • (2013) Lancet , vol.381 , pp. 1203-1210
    • Rummel, M.J.1    Niederle, N.2    Maschmeyer, G.3
  • 6
    • 84900423736 scopus 로고    scopus 로고
    • Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
    • Flinn IW, van der Jagt R, Kahl BS et al. Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944-2952.
    • (2014) Blood , vol.123 , pp. 2944-2952
    • Flinn, I.W.1    van der Jagt, R.2    Kahl, B.S.3
  • 7
    • 84872054301 scopus 로고    scopus 로고
    • CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
    • Delarue R, Haioun C, Ribrag V et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013; 121: 48-53.
    • (2013) Blood , vol.121 , pp. 48-53
    • Delarue, R.1    Haioun, C.2    Ribrag, V.3
  • 8
    • 84864715966 scopus 로고    scopus 로고
    • Treatment of older patients with mantle-cell lymphoma
    • Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531.
    • (2012) N Engl J Med , vol.367 , pp. 520-531
    • Kluin-Nelemans, H.C.1    Hoster, E.2    Hermine, O.3
  • 9
    • 79959576404 scopus 로고    scopus 로고
    • Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report
    • Witzig TE, Fishkin P, Gordon LI et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma 2011; 52: 1188-1199.
    • (2011) Leuk Lymphoma , vol.52 , pp. 1188-1199
    • Witzig, T.E.1    Fishkin, P.2    Gordon, L.I.3
  • 10
    • 0037262242 scopus 로고    scopus 로고
    • Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
    • Lentzsch S, LeBlanc R, Podar K et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17: 41-44.
    • (2003) Leukemia , vol.17 , pp. 41-44
    • Lentzsch, S.1    LeBlanc, R.2    Podar, K.3
  • 11
    • 33745961875 scopus 로고    scopus 로고
    • Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
    • Chang DH, Liu N, Klimek V et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006; 108: 618-621.
    • (2006) Blood , vol.108 , pp. 618-621
    • Chang, D.H.1    Liu, N.2    Klimek, V.3
  • 12
    • 33744536515 scopus 로고    scopus 로고
    • Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly
    • Gandhi AK, Kang J, Naziruddin S et al. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006; 30: 849-858.
    • (2006) Leuk Res , vol.30 , pp. 849-858
    • Gandhi, A.K.1    Kang, J.2    Naziruddin, S.3
  • 13
    • 65549151712 scopus 로고    scopus 로고
    • E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction
    • Gorgun G, Ramsay AG, Holderried TA et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009; 106: 6250-6255.
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 6250-6255
    • Gorgun, G.1    Ramsay, A.G.2    Holderried, T.A.3
  • 14
    • 73949116990 scopus 로고    scopus 로고
    • Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
    • Ramsay AG, Clear AJ, Kelly G et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114: 4713-4720.
    • (2009) Blood , vol.114 , pp. 4713-4720
    • Ramsay, A.G.1    Clear, A.J.2    Kelly, G.3
  • 15
    • 33846665934 scopus 로고    scopus 로고
    • Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
    • Verhelle D, Corral LG, Wong K et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746-755.
    • (2007) Cancer Res , vol.67 , pp. 746-755
    • Verhelle, D.1    Corral, L.G.2    Wong, K.3
  • 16
    • 69549116054 scopus 로고    scopus 로고
    • Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
    • Zhang L, Qian Z, Cai Z et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009; 84: 553-559.
    • (2009) Am J Hematol , vol.84 , pp. 553-559
    • Zhang, L.1    Qian, Z.2    Cai, Z.3
  • 17
    • 51649123319 scopus 로고    scopus 로고
    • Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells
    • Wu L, Adams M, Carter T et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14: 4650-4657.
    • (2008) Clin Cancer Res , vol.14 , pp. 4650-4657
    • Wu, L.1    Adams, M.2    Carter, T.3
  • 18
    • 28844472902 scopus 로고    scopus 로고
    • Lenalidomide and thalidomide: mechanisms of action-similarities and differences
    • Anderson KC. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 2005; 42: S3-S8.
    • (2005) Semin Hematol , vol.42 , pp. S3-S8
    • Anderson, K.C.1
  • 20
    • 79952106893 scopus 로고    scopus 로고
    • Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo
    • Qian Z, Zhang L, Cai Z et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 2011; 35: 380-386.
    • (2011) Leuk Res , vol.35 , pp. 380-386
    • Qian, Z.1    Zhang, L.2    Cai, Z.3
  • 21
    • 84873076585 scopus 로고    scopus 로고
    • Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
    • Zhang LH, Kosek J, Wang M et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 2013; 160: 487-502.
    • (2013) Br J Haematol , vol.160 , pp. 487-502
    • Zhang, L.H.1    Kosek, J.2    Wang, M.3
  • 22
    • 84862152044 scopus 로고    scopus 로고
    • Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
    • Yang Y, Shaffer AL 3rd, Emre NC et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723-737.
    • (2012) Cancer Cell , vol.21 , pp. 723-737
    • Yang, Y.1    Shaffer, A.L.2    Emre, N.C.3
  • 24
    • 73949145763 scopus 로고    scopus 로고
    • Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma
    • Witzig TE, Wiernik PH, Moore T et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009; 27: 5404-5409.
    • (2009) J Clin Oncol , vol.27 , pp. 5404-5409
    • Witzig, T.E.1    Wiernik, P.H.2    Moore, T.3
  • 25
    • 54449095901 scopus 로고    scopus 로고
    • Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
    • Wiernik PH, Lossos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952-4957.
    • (2008) J Clin Oncol , vol.26 , pp. 4952-4957
    • Wiernik, P.H.1    Lossos, I.S.2    Tuscano, J.M.3
  • 26
    • 64149112784 scopus 로고    scopus 로고
    • Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
    • Habermann TM, Lossos IS, Justice G et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145: 344-349.
    • (2009) Br J Haematol , vol.145 , pp. 344-349
    • Habermann, T.M.1    Lossos, I.S.2    Justice, G.3
  • 27
    • 79959722615 scopus 로고    scopus 로고
    • An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
    • Witzig TE, Vose JM, Zinzani PL et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
    • (2011) Ann Oncol , vol.22 , pp. 1622-1627
    • Witzig, T.E.1    Vose, J.M.2    Zinzani, P.L.3
  • 28
    • 84887030194 scopus 로고    scopus 로고
    • Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
    • Zinzani PL, Vose JM, Czuczman MS et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013; 24: 2892-2897.
    • (2013) Ann Oncol , vol.24 , pp. 2892-2897
    • Zinzani, P.L.1    Vose, J.M.2    Czuczman, M.S.3
  • 29
    • 84889099537 scopus 로고    scopus 로고
    • Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study
    • Goy A, Sinha R, Williams ME et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688-3695.
    • (2013) J Clin Oncol , vol.31 , pp. 3688-3695
    • Goy, A.1    Sinha, R.2    Williams, M.E.3
  • 30
    • 84941625318 scopus 로고    scopus 로고
    • Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
    • ASCO Annual Meeting Abstracts
    • Witzig TE, Vose J, Zinzani PL et al. Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. J Clin Oncol 2013; 31 (suppl; Abstract 8533; ASCO Annual Meeting Abstracts).
    • (2013) J Clin Oncol , vol.31
    • Witzig, T.E.1    Vose, J.2    Zinzani, P.L.3
  • 31
    • 84941663404 scopus 로고    scopus 로고
    • Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: a combined analysis from the MCL-001, NHL-002, and NHL-003 studies
    • EHA Annual Meeting Abstracts
    • Witzig TE, Vose J, Zinzani PL et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: a combined analysis from the MCL-001, NHL-002, and NHL-003 studies. Haematologica 2013; 98 (suppl; Abstract P305; EHA Annual Meeting Abstracts).
    • (2013) Haematologica , vol.98
    • Witzig, T.E.1    Vose, J.2    Zinzani, P.L.3
  • 32
    • 84975856533 scopus 로고    scopus 로고
    • Lenalidomide monotherapy is clinically active in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): a pooled analysis of data from phase II studies (NHL-002/003)
    • EHA Annual Meeting Abstracts
    • Czuczman M, Vose J, Zinzani PL et al. Lenalidomide monotherapy is clinically active in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): a pooled analysis of data from phase II studies (NHL-002/003). Haematologica 2010; 95: (suppl 2; EHA Annual Meeting Abstracts).
    • (2010) Haematologica , vol.95
    • Czuczman, M.1    Vose, J.2    Zinzani, P.L.3
  • 33
    • 84866875871 scopus 로고    scopus 로고
    • Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
    • Eve HE, Carey S, Richardson SJ et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012; 159: 154-163.
    • (2012) Br J Haematol , vol.159 , pp. 154-163
    • Eve, H.E.1    Carey, S.2    Richardson, S.J.3
  • 34
    • 84881664038 scopus 로고    scopus 로고
    • Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
    • Vose JM, Habermann TM, Czuczman MS et al. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol 2013; 162: 639-647.
    • (2013) Br J Haematol , vol.162 , pp. 639-647
    • Vose, J.M.1    Habermann, T.M.2    Czuczman, M.S.3
  • 35
    • 84929117400 scopus 로고    scopus 로고
    • Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: subgroup analysis of the MCL-001 study
    • ASCO Annual Meeting Abstracts
    • Williams ME, Goy A, Sinha R et al. Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: subgroup analysis of the MCL-001 study. J Clin Oncol 2013; 31: (suppl; Abstract 8534; ASCO Annual Meeting Abstracts).
    • (2013) J Clin Oncol , vol.31
    • Williams, M.E.1    Goy, A.2    Sinha, R.3
  • 36
    • 84928022568 scopus 로고    scopus 로고
    • Updated efficacy and safety, and exploratory Ki-67 results for the MCL-001 study of lenalidomide in mantle cell lymphoma patients who relapsed or were refractory to bortezomib
    • ASH Annual Meeting Abstracts
    • Goy A, Williams ME, Besisik SK et al. Updated efficacy and safety, and exploratory Ki-67 results for the MCL-001 study of lenalidomide in mantle cell lymphoma patients who relapsed or were refractory to bortezomib. Blood 2013; 122 (Abstract 3057; ASH Annual Meeting Abstracts).
    • (2013) Blood , vol.122
    • Goy, A.1    Williams, M.E.2    Besisik, S.K.3
  • 37
    • 80053502780 scopus 로고    scopus 로고
    • Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-celllike than in germinal center B-cell-like phenotype
    • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-celllike than in germinal center B-cell-like phenotype. Cancer 2011; 117: 5058-5066.
    • (2011) Cancer , vol.117 , pp. 5058-5066
    • Hernandez-Ilizaliturri, F.J.1    Deeb, G.2    Zinzani, P.L.3
  • 38
    • 84899427423 scopus 로고    scopus 로고
    • Lenalidomide is effective in heavily pretreated non-Hodgkin lymphoma (NHL): analysis of a retrospective data collection
    • ASH Annual Meeting Abstracts
    • Rigacci L, Vitolo U, Cox MC et al. Lenalidomide is effective in heavily pretreated non-Hodgkin lymphoma (NHL): analysis of a retrospective data collection. Blood 2012; 120 (Abstract 3694; ASH Annual Meeting Abstracts).
    • (2012) Blood , vol.120
    • Rigacci, L.1    Vitolo, U.2    Cox, M.C.3
  • 39
    • 23844435619 scopus 로고    scopus 로고
    • Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
    • Hernandez-Ilizaliturri FJ, Reddy N, Holkova B et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005; 11: 5984-5992.
    • (2005) Clin Cancer Res , vol.11 , pp. 5984-5992
    • Hernandez-Ilizaliturri, F.J.1    Reddy, N.2    Holkova, B.3
  • 40
    • 36849024949 scopus 로고    scopus 로고
    • Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo
    • Reddy N, Hernandez-Ilizaliturri FJ, Deeb G et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140: 36-45.
    • (2008) Br J Haematol , vol.140 , pp. 36-45
    • Reddy, N.1    Hernandez-Ilizaliturri, F.J.2    Deeb, G.3
  • 41
    • 84863107308 scopus 로고    scopus 로고
    • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
    • Wang M, Fayad L, Wagner-Bartak N et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723.
    • (2012) Lancet Oncol , vol.13 , pp. 716-723
    • Wang, M.1    Fayad, L.2    Wagner-Bartak, N.3
  • 42
    • 84927730011 scopus 로고    scopus 로고
    • Sustained remission with the combination biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: a multicenter phase II study report
    • ASH Annual Meeting Abstracts
    • Ruan J, Martin P, Shah BD et al. Sustained remission with the combination biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: a multicenter phase II study report. Blood 2014; 124 (21; Abstract 625; ASH Annual Meeting Abstracts).
    • (2014) Blood , vol.124 , Issue.21
    • Ruan, J.1    Martin, P.2    Shah, B.D.3
  • 43
    • 84883742025 scopus 로고    scopus 로고
    • Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
    • Wang M, Fowler N, Wagner-Bartak N et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27: 1902-1909.
    • (2013) Leukemia , vol.27 , pp. 1902-1909
    • Wang, M.1    Fowler, N.2    Wagner-Bartak, N.3
  • 44
    • 84857654592 scopus 로고    scopus 로고
    • Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial
    • Zinzani PL, Pellegrini C, Gandolfi L et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011; 11: 462-466.
    • (2011) Clin Lymphoma Myeloma Leuk , vol.11 , pp. 462-466
    • Zinzani, P.L.1    Pellegrini, C.2    Gandolfi, L.3
  • 45
    • 84889004860 scopus 로고    scopus 로고
    • Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients
    • Zinzani PL, Pellegrini C, Derenzini E et al. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol 2013; 31: 223-224.
    • (2013) Hematol Oncol , vol.31 , pp. 223-224
    • Zinzani, P.L.1    Pellegrini, C.2    Derenzini, E.3
  • 46
    • 84898467895 scopus 로고    scopus 로고
    • Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma
    • Tuscano JM, Dutia M, Chee K et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol 2014; 165: 375-381.
    • (2014) Br J Haematol , vol.165 , pp. 375-381
    • Tuscano, J.M.1    Dutia, M.2    Chee, K.3
  • 47
    • 84868193664 scopus 로고    scopus 로고
    • CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma
    • ASCO Annual Meeting Abstracts
    • Leonard J, Jung SH, Johnson JL et al. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol 2012; 30 (Abstract 8000; ASCO Annual Meeting Abstracts).
    • (2012) J Clin Oncol , vol.30
    • Leonard, J.1    Jung, S.H.2    Johnson, J.L.3
  • 48
    • 84901721963 scopus 로고    scopus 로고
    • CALGB 50803(ALLIANCE): a phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma
    • ICML Abstracts
    • Martin P, Jung S, Johnson J et al. CALGB 50803(ALLIANCE): a phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Hematol Oncol 2013; 31 (suppl I; 117 Abstract 063; ICML Abstracts).
    • (2013) Hematol Oncol , vol.31 , pp. 117
    • Martin, P.1    Jung, S.2    Johnson, J.3
  • 49
    • 84908574357 scopus 로고    scopus 로고
    • Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
    • Fowler NH, Davis RE, Rawal S et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014; 15: 1311-1318.
    • (2014) Lancet Oncol , vol.15 , pp. 1311-1318
    • Fowler, N.H.1    Davis, R.E.2    Rawal, S.3
  • 50
    • 84857740069 scopus 로고    scopus 로고
    • Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
    • Zaja F, De Luca S, Vitolo U et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416-422.
    • (2012) Haematologica , vol.97 , pp. 416-422
    • Zaja, F.1    De Luca, S.2    Vitolo, U.3
  • 51
    • 84891868901 scopus 로고    scopus 로고
    • Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas
    • Ahmadi T, Chong EA, Gordon A et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer 2014; 120: 222-228.
    • (2014) Cancer , vol.120 , pp. 222-228
    • Ahmadi, T.1    Chong, E.A.2    Gordon, A.3
  • 52
    • 84929119124 scopus 로고    scopus 로고
    • Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)
    • Morrison VA, Jung SH, Johnson J et al. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501). Leuk Lymphoma 2014; 1-14. doi:10.3109/10428194.2014.938333.
    • (2014) Leuk Lymphoma , pp. 1-14
    • Morrison, V.A.1    Jung, S.H.2    Johnson, J.3
  • 53
    • 84909967627 scopus 로고    scopus 로고
    • Rituximab, lenalidomide, and bortezomib in the first-line or second-line treatment of patients with mantle cell lymphoma: a phase I/II trial
    • ASH Annual Meeting Abstracts
    • Flinn IW, Mainwaring M, Peacock N et al. Rituximab, lenalidomide, and bortezomib in the first-line or second-line treatment of patients with mantle cell lymphoma: a phase I/II trial. Blood 2012; 120 (Abstract 2748; ASH Annual Meeting Abstracts).
    • (2012) Blood , vol.120
    • Flinn, I.W.1    Mainwaring, M.2    Peacock, N.3
  • 54
    • 84921764017 scopus 로고    scopus 로고
    • Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study
    • Nowakowski GS, LaPlant B, Macon WR et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 2014; 33: 251-257.
    • (2014) J Clin Oncol , vol.33 , pp. 251-257
    • Nowakowski, G.S.1    LaPlant, B.2    Macon, W.R.3
  • 55
    • 84983215647 scopus 로고    scopus 로고
    • Lenalidomide in combination with RCHOP (R2-CHOP) in patients with high burden follicular lymphoma: Phase 2 study
    • ASH Annual Meeting Abstracts
    • Tilly H, Morschhauser F, Casasnovas O et al. Lenalidomide in combination with RCHOP (R2-CHOP) in patients with high burden follicular lymphoma: Phase 2 study. Blood 2013; 122 (Abstract 248; ASH Annual Meeting Abstracts).
    • (2013) Blood , vol.122
    • Tilly, H.1    Morschhauser, F.2    Casasnovas, O.3
  • 56
    • 84901391325 scopus 로고    scopus 로고
    • Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
    • Vitolo U, Chiappella A, Franceschetti S et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014; 15: 730-737.
    • (2014) Lancet Oncol , vol.15 , pp. 730-737
    • Vitolo, U.1    Chiappella, A.2    Franceschetti, S.3
  • 57
    • 84929093161 scopus 로고    scopus 로고
    • Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: preliminary results from the Nordic Lymphoma Group MCL4 (LENABERIT) phase I-II trial
    • ASH Annual Meeting Abstracts
    • Jerkeman M, Albertsson-Lindblad A, Kolstad A et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: preliminary results from the Nordic Lymphoma Group MCL4 (LENABERIT) phase I-II trial. Blood 2013; 122 (Abstract 4377; ASH Annual Meeting Abstracts).
    • (2013) Blood , vol.122
    • Jerkeman, M.1    Albertsson-Lindblad, A.2    Kolstad, A.3
  • 58
    • 36349023319 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    • Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
    • (2007) N Engl J Med , vol.357 , pp. 2123-2132
    • Dimopoulos, M.1    Spencer, A.2    Attal, M.3
  • 59
    • 36349010285 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    • Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
    • (2007) N Engl J Med , vol.357 , pp. 2133-2142
    • Weber, D.M.1    Chen, C.2    Niesvizky, R.3
  • 60
    • 84867329976 scopus 로고    scopus 로고
    • Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines
    • Cosenza M, Civallero M, Grisendi G et al. Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines. Ann Hematol 2012; 91: 1613-1622.
    • (2012) Ann Hematol , vol.91 , pp. 1613-1622
    • Cosenza, M.1    Civallero, M.2    Grisendi, G.3
  • 61
    • 83555173455 scopus 로고    scopus 로고
    • Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
    • Nowakowski GS, LaPlant B, Habermann TM et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 2011; 25: 1877-1881.
    • (2011) Leukemia , vol.25 , pp. 1877-1881
    • Nowakowski, G.S.1    LaPlant, B.2    Habermann, T.M.3
  • 62
    • 84873571469 scopus 로고    scopus 로고
    • Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma
    • Tilly H, Morschhauser F, Salles G et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 2013; 27: 252-255.
    • (2013) Leukemia , vol.27 , pp. 252-255
    • Tilly, H.1    Morschhauser, F.2    Salles, G.3
  • 63
    • 84887011781 scopus 로고    scopus 로고
    • Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi
    • Chiappella A, Tucci A, Castellino A et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica 2013; 98: 1732-1738.
    • (2013) Haematologica , vol.98 , pp. 1732-1738
    • Chiappella, A.1    Tucci, A.2    Castellino, A.3
  • 64
    • 84880259494 scopus 로고    scopus 로고
    • Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
    • Hitz F, Fischer N, Pabst T et al. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol 2013; 92: 1033-1040.
    • (2013) Ann Hematol , vol.92 , pp. 1033-1040
    • Hitz, F.1    Fischer, N.2    Pabst, T.3
  • 65
    • 84862212752 scopus 로고    scopus 로고
    • Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial
    • ASH Annual Meeting Abstracts
    • Jerkeman M, Kolstad A, Laurell A et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial. Blood 2011; 118 (Abstract 2700; ASH Annual Meeting Abstracts).
    • (2011) Blood , vol.118
    • Jerkeman, M.1    Kolstad, A.2    Laurell, A.3
  • 66
    • 79958043675 scopus 로고    scopus 로고
    • Bethesda, MD: National Cancer Institute 2015. based on November 2013 SEER data submission, posted to the SEER website, April 2014
    • Howlader N, Noone AM, Krapcho M et al. (eds). SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute 2015. http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER website, April 2014.
    • SEER Cancer Statistics Review, 1975-2007
    • Howlader, N.1    Noone, A.M.2    Krapcho, M.3
  • 67
    • 79960431409 scopus 로고    scopus 로고
    • Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified
    • Zinzani PL, Pellegrini C, Broccoli A et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 2011; 52: 1585-1588.
    • (2011) Leuk Lymphoma , vol.52 , pp. 1585-1588
    • Zinzani, P.L.1    Pellegrini, C.2    Broccoli, A.3
  • 68
    • 81055123994 scopus 로고    scopus 로고
    • A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
    • Fehniger TA, Larson S, Trinkaus K et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118: 5119-5125.
    • (2011) Blood , vol.118 , pp. 5119-5125
    • Fehniger, T.A.1    Larson, S.2    Trinkaus, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.